Mark Germain - 16 Jun 2026 Form 4 Insider Report for Scinai Immunotherapeutics Ltd. (SCNI)

SEC form
4
Accepted by SEC
18 Jun 2026, 14:51:11 UTC
Prior SEC filing
18 Mar 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Mark Germain filed Form 4 for Scinai Immunotherapeutics Ltd. (SCNI) on 18 Jun 2026.

Key facts

  • This page summarizes Mark Germain's Form 4 filing for Scinai Immunotherapeutics Ltd. (SCNI).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Jun 2026, 14:51.

Change

  • Previous filing in this sequence was filed on 18 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001195498 Primary reporting owner

GERMAIN MARK

Relationship
Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCNI transaction

Ordinary Shares

Award

Transaction value
Shares
+120,000,000
Change %
Price
$0.000000*
Shares after
120,000,000
Date
16 Jun 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

Footnote F2

Includes 120,000,000 Ordinary Shares represented by restricted share units granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .